The regulatory approval of PARPi monotherapy in patients with HRD tumours has massively stimulated research in DDR inhibitors, particularly those targeting ATR and CHK1, which also have the potential to reverse PARPi resistance. The gene discussed is ATR; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.